Onchilles Pharma Inc
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | Neutrophil elastase (ELANE) pathway - N17350 acts as a direct protease/enzyme therapeutic rather than a receptor-binding inhibitorBiologic (subtype unspecified) | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
No financial reports recorded.